Toronto Raptors coach Nick Nurse discussed why his team got off to a slow start against the Los Angeles Lakers.
Toronto Raptors coach Nick Nurse discussed why his team got off to a slow start against the Los Angeles Lakers.
Facebook has signed a deal to buy renewable energy in India from a local firm's wind power project, the social media giant's first such deal in the South Asian nation, the companies said on Thursday. The 32 megawatt wind power project, located in southern Karnataka state, is part of a larger portfolio of wind and solar projects that Facebook and Mumbai-based CleanMax are working together on for supplying renewable power into India's electrical grid, they said in a joint statement. CleanMax will own and operate the projects, while Facebook will buy the power off the grid using environmental attribute certificates, or carbon credits, the companies said.
Naked Wines on Thursday reported better-than-expected annual sales growth of about 68% as the online wine seller benefited from a surge in orders during the pandemic-led lockdowns, especially in the United States. With most restaurants and bars shut for long durations over the past one year, companies such as Naked Wines benefited as more people ordered wine home. London-listed Naked Wines said group sales for the fiscal year ending March 29, 2021, grew 68%, ahead of its growth forecast of 55%-65%.
‘People think I must be crazy’: Phil Brown targets Southend rescue actSeasiders have turned to their former manager in a late push to avert relegation from League Two after long period of strife Phil Brown gives instructions to his players during Southend’s goalless draw at home to Crawley in his first match back at the club. Photograph: Holly Allison/TPI/Shutterstock
US company illegally peddling ‘miracle cure’ bleach for new Covid variantsOclo in Florida exploiting fears around new virus strains by selling chlorine dioxide, despite FDA warnings against fraudulent ‘cures’ The appearance of a new marketing push out of Miami by peddlers of the bleach ‘cure’ signals the FDA’s uphill struggle in trying to control the potentially lethal trade. Photograph: Danilo Balderrama/Reuters
UN outlines plan to close camps housing 430,000 refugees in KenyaProposals follow Kenyan government’s ultimatum to UN refugee agency to close Dadaab and Kakuma camps Children with Unicef backpacks in Kalobeyei, an overspill camp near Kakuma. Some 430,000 refugees from 15 countries live in Dadaab and Kakuma camps. Photograph: Bernd von Jutrczenka/dpa/Alamy
With a design inspired by a book, Bang & Olufsen's Beosound Emerge is an impressively slim and full-featured speaker.
The top 20 hottest markets were determined based on the number of unique views per property and the number of days a listing stayed active in March
The defense will call at least one more witness in the trial of former Minneapolis police officer Derek Chauvin, charged in George Floyd's death.
A spokesman for the ex-PM said he will respond ‘positively’ to any request to give evidence on the financial firm’s collapse.
Acquisition will add secure fund portals and fund marketing tools to Confluence’s award-winning platform of solutionsPittsburgh, PA, April 15, 2021 (GLOBE NEWSWIRE) -- Confluence Technologies, a global technology solutions provider helping the investment management industry solve complex investment data challenges, today announced that it has reached an agreement in principle to acquire Fundpeak, a highly respected global provider of secure fund portals and marketing tools such as fund factsheets and websites. Fundpeak’s solutions help funds produce multilingual factsheets for marketing purposes and to meet local regulatory reporting requirements in more than 30 countries. Additionally, the company’s custom-designed fund portal integrates directly into client websites, enabling automated internal reporting for portfolio managers and external reporting to shareholders and clients. Confluence will integrate Fundpeak’s factsheets product and customized portals into its award-winning platform of solutions, providing capabilities at a scale previously unavailable to the industry. The addition of these capabilities represents Confluence’s commitment to expand its offering and provide solutions to asset managers, global fund administrators and other service providers across the investment lifecycle. The transaction is expected to close in the second quarter of 2021 and is a testament to Confluence’s dedication to advancing its industry-leading offering through ongoing investment in R&D and acquisitions. Factsheets and other investor reporting comprise a growing area of compliance complexity for fund managers as they work to provide digital data and analytics to their end-investor clients. Fundpeak’s solutions address recent regulations including the European Union’s Key Investor Information Document (KIID) and Packaged Retail and Insurance-based Investment Products (PRIIPs) requirements which are expected to be emulated in other regions. “As we explore every avenue to enhance our solutions, Confluence is excited to be acquiring Fundpeak, a company with tremendous technological capabilities and a focus on providing clients with transformative tools to help the market best service fund shareholders,” said Mark Evans, Confluence’s CEO and founder. “Adding Fundpeak’s suite of services to our current shareholder reporting offering will provide additional value to an industry that recognizes the efficiencies of curating and normalizing data only once for client reporting and distribution.” Fundpeak’s founder and managing director Pavel Topol commented, “We’re thrilled to be joining an organization with which we share common goals and values, including our dedication to solving the complex data and reporting challenges facing the investment management industry today. Confluence’s mission to help clients reduce risk and increase efficiency mirrors what we have tried to do at Fundpeak from the beginning. We’re pleased that our clients and partners will have access to Confluence’s innovative tools and technologies to help improve and grow their own businesses.” About Confluence As a leading global technology solutions provider to the investment management industry, Confluence helps clients solve complex investment data challenges across the front, middle and back office. From innovative portfolio analytics to regulatory and financial reporting solutions, Confluence invests in the latest technology and data and in its team of industry experts to meet the evolving needs of asset managers and service providers. Headquartered in Pittsburgh, PA, Confluence services over 400 clients in 39 countries, with locations across Europe, North America, South Africa, Australia and Asia. For more information, visit www.confluence.com CONTACT: Michael Kingsley Forefront Communications Group, Inc. + 1 212-320-8984 firstname.lastname@example.org
Study concludes that psilocybin findings should be explored further in larger studiesLondon, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD. The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of daily placebo capsules. The escitalopram arm received two doses of 1mg psilocybin (presumed negligible effect) three weeks apart, with equivalent psychological support to the psilocybin arm, plus six weeks of daily escitalopram capsules, 10mg for the first three weeks titrated to 20mg for the following three weeks. The study authors, from Imperial College London, noted that the study was not powered to detect a difference between psilocybin and escitalopram. As reported in the NEJM, the primary efficacy measure, the change from baseline in the self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16) total score at six weeks, did not show a significant difference between the two groups, with a two point difference favouring the psilocybin group compared with the escitalopram group. This trend favouring psilocybin was present from week one. Secondary outcomes including clinician-rated depression scales, response and remission, signalled the antidepressant effects of both agents; psilocybin showed numerical advantages on clinical measures compared with escitalopram. On the clinician-rated depression scales, the change from baseline at week six on the Montgomery-Asberg Depression Rating Scale (MADRS), showed a 7.2 point treatment difference favouring psilocybin, while the Hamilton Depression Rating Scale (HAM-D-17) showed a 5.3 point treatment difference favouring psilocybin. Response rates (a 50% or greater reduction on the QIDS-SR-16 total score from baseline) at week six were 70.2% for the psilocybin arm compared with 48.0% for the escitalopram arm, and remission rates (defined as a QIDS-SR-16 total score ≤5) at week six were 57.1% and 29.1%, respectively. Similar patterns favouring psilocybin were found in other secondary endpoints measuring work and social functioning, anxiety, avoidance, anhedonia, and wellbeing. Such secondary endpoints were uncorrected for multiplicity. Adverse event rates and severity were largely comparable across conditions. Adverse events in the psilocybin arm were typically transient, occurring and resolving within 24 hours of dosing days, with the most commonly reported adverse event being transient headaches. No Serious Adverse Events were reported. “In a field of research where it is very difficult to separate treatments in head-to-head comparative efficacy trials, this study found signals favouring psilocybin therapy over escitalopram. This is an encouraging investigator-initiated study that supports the need for additional clinical investigations in larger, well-powered studies to more accurately determine the efficacy of COMP360 psilocybin in MDD”, said George Goldsmith, CEO and Co-founder of COMPASS Pathways. “At COMPASS, we are already committed to a full clinical development programme of psilocybin therapy in treatment-resistant depression, and we know there is much more work to be done so that we can bring evidence-based innovation to patients who have run out of options in a number of mental health illnesses.” -Ends- About COMPASS Pathways COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com Availability of other information about COMPASS Pathways Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, the efficacy of COMP360 psilocybin therapy as a treatment for depression, COMPASS’s business strategy and goals, COMPASS’s ability to continue to advance its research, including COMP360, and COMPASS’s expectations regarding the benefits of its psilocybin therapy, including COMP360. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof. Enquiries Media: Tracy Cheung, email@example.com, +44 7966 309024 Investors: Stephen Schultz, firstname.lastname@example.org, +1 401 290 7423
His ‘n’ hers dressing was once the scourge of red carpets. Then TikTok came along
Bermuda, 15 April 2021: Avance Gas Holding Ltd (OSE: AGAS) announces that the annual report for the financial year ended 31 December 2020 is published today. A pdf-version of the annual report is attached and is also available on the company's website www.avancegas.com (http://www.avancegas.com).For further queries, please contact: Randi Navdal bekkelund, CFO Tel: +47 22 00 48 29 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Attachment Avance Gas Annual Report 2020
J.P. Morgan expands its use of the Acin Platform and peer-to-peer Acin Network for managing operational risk, across its Global Markets business.
Is One Shot Keto True Weight Loss in a Bottle or Just a Big Hoax? Find Out What The Experts Have to Say In Our New Ground-Breaking Report!Philadelphia, PA, April 15, 2021 (GLOBE NEWSWIRE) -- One Shot Keto Supplement Reviews: Updated Ground-Breaking Report Provides Valuable Information Just Released. IMPORTANT: Shocking New One Shot Keto Report - This May Change Your Mind! One Shot Keto is a ketosis-supporting supplement that complements a ketogenic diet and accelerates weight loss. The Limitless Company’s supplement is marketed with the aim of offering a viable solution to losing weight that has a long-lasting impact. Thousands of loyal consumers have found success in their weight loss journeys thanks to One Shot Keto supplements. HUGE SAVINGS TODAY: Click Here to Get One Shot Keto at an Exclusive Discounted Price The primary ingredient in One Shot Keto is 100% Beta-hydroxybutyrate or BHB. beta-hydroxybutyrate (BHB) is a Ketone salt that consists of a ketone body combined to a mineral ion, often sodium. So for our review we will start off by examining the real truth about BHB. There are several companies selling this form of exogenous ketone, and it is here that we see the massive marketing campaigns and broad benefits statements. The REAL One Shot Keto Testimonial – “You Will Not Believe What She Said!” What are the Experts saying about Beta-hydroxybutyrate (BHB)? Since One Shot Keto uses BHB as its main ingredient, we contacted our research analyst Cindy Walters to find out exactly what the experts are saying about BHB salts and to also speak to a few experts ourselves to get the real scoop. Let’s start with Dietdocor.com They decided to write an article explaining an experiement (study) they conducted with a medical review by Dr. Andreas Eenfeldt, MD (Kim) from dietdoctor.com researched the subject and designed and executed the experiment under the guidance and supervision of Dr. Andreas Eenfeldt, who communicated with her during the process to ensure that the experiment design and execution adhered to scientific rigor (to the greatest extent possible) and who also edited their write-up for accuracy and trustworthiness. Additionally, she collaborated with other keto experts and researchers to solicit input on the experiment's design and data analysis. This benefit claims tested were: Blood ketonesMental performancePhysical performance She conducted the testing over five days, allowing at least two days between each day of testing to allow the teammates time to recover from the physical performance test. She needed five days because she used a placebo (an artificially flavored beverage devoid of caffeine) in addition to the four brands tested. The teammates were unaware that one of the supplements they were taking was a placebo. Additionally, she gave everyone a different supplement each time to rule out the possibility that any progress in the tests was due to people actually getting better at them over time. This was not a scientific experiment conducted under controlled laboratory conditions, and as a result, she could only draw speculative conclusions from some of the results. Nonetheless, conducting the research should give the majority of people a reasonable understanding of how well ketone supplements demonstrate the noticeable benefits they are marketed to provide and give a sufficient basis for deciding whether or not to purchase them. The Experimental Test Results: "The BHB ketone supplements did not work especially well." Blood ketones: It was anticipated that consuming a ketone supplement would result in an increase in blood ketones, but an average increase of 0.33 mmol/L is very slight. Other performance indicators, such as physical and mental performance, also performed poorly. Dr. Ryan Lowery, Ph.D. indicated that she might have conducted the tests too soon after taking the supplements, as blood ketones usually peak at 30 minutes. The products used in this study are as follows: KegenixKetondPruvitPerfect Keto One Shot Keto was not part of this study! Since these other products are not the same formulation as One Shot Keto, we had to find out how well One Shot Keto is actually working for users. We Have Now Conducted Our Own Online Survey of One Shot Keto Users. Given that One Shot Keto is one of the most popular weight loss supplements on the market right now, we thought the best way to obtain accurate information about its performance was to conduct this survey. With that in mind, there was no way to verify whether or not participants consumed One Shot Keto, so please be aware of that. 82% of respondents to our survey reported that they did lose weight by using One Shot Keto. 58% reported to have improved their energy levels. 34% reported increased focus. Additionally, 86% of participants reported having control over their appetite. Our survey is still open, and if you are a One Shot Keto user and would like to participate, please contact us at email@example.com. We'd love to include your results in our upcoming update to our One Shot Keto survey. Let us now go into more detail about One Shot Keto Our One Shot Keto Review: What is One Shot Keto? One Shot Keto was introduced to the market as one of the most potent keto weight loss supplements, using an exogenous ketones-based formula to induce nutritional ketosis in the body. One Shot Keto, according to their website, provides enough ketones to assist you in adhering to your keto diet regime more effectively. One Shot Keto pills are formulated to assist you in obtaining an optimal level of ketone bodies in your blood. This way, the body enters ketosis much more quickly, allowing you to lose excess fat more quickly and feel more energized than before. How Does One Shot Keto Work? According to the official website, One Shot Keto essentially supplies the body with vital nutrients that aid in the body's transition into ketosis. When in ketosis, the body is flooded with ketones, which are nothing more than microscopic chemical bodies formed in the liver as stored fats are broken down. As you are probably aware, when the body reaches ketosis, it obtains energy from stored fat rather than carbohydrates. However, when you avoid providing your body with carbohydrates or glucose, it begins to search for an alternative energy source, which is your stored fat. And when the body begins to burn fat for energy, ketones are produced as a byproduct, and when the ketones reach a certain level, the body enters ketosis. This is how One Shot Keto contributes to this process. These capsules contain an electrolyte solution that mimics the effect of accumulated fat in the body. When the capsule enters your gut, it breaks down and releases pre-made ketones to help the body enter ketosis. Additionally, all of the ingredients in this supplement are entirely normal. However, it's important to keep in mind that outcomes differ from person to person, which means that the time required for One Shot Keto to take effect varies as well. Are Complaints About One Shot Keto Scams Valid? Depending on where you shop or look for genuine One Shot Keto customer feedback, there are a few obvious concerns that must be handled correctly in order to maximize your investment and ensure consumer security against counterfeit OneShot Keto pills. There are two critical caveats to bear in mind immediately: 1) ALL One Shot Keto scam complaints about negative side effects and severe adverse reactions found online originate from non-legitimate vendors and marketplaces selling inferior ripoff weight loss diet supplements under the same brand name. 2) One Shot Keto Shark Tank advertisements are 100 percent fraudulent and should be avoided. Of course, none of these has anything to do with the real ketosis-inducing fat burner, but there are significant risks associated with purchasing counterfeit Limitless One Shot Keto diet pills from illegal third-party retail sites. Between the One Shot Keto side effects reported by customers who purchased from Amazon, Ebay, or Walmart, and the same brand's multiple product lists that do not have a money-back guarantee or company accountability, it is thankfully quite convenient to prevent any of these One Shot Keto consumer issues by ordering directly from the official website. Then, as previously said, it is prudent not to believe or be led to believe that Shark Tank endorses One Shot Keto pills, as some fabricated online advertisements would have you believe. To date, no ketone weight loss supplement, especially the One Shot Keto type, has ever been featured on the Shark Tank television show. However, the irony is that One Shot Keto's ingredients are among the most diverse and robust available for a ketosis boosting supplement, so it does not need phony advertorials to highlight its high-profile extracts and ketogenic diet-friendly benefits. Where Can I Buy One Shot Keto? One Shot Keto is available exclusively via their official website. The manufacturers' decision to not produce this supplement in other countries is a wise one, since it protects consumers from falling for fraudulent manufacturers selling fake goods. Simply visit the official site here and put in your order. The following are the available pricing options: $69.99 for a single bottle (includes free shipping)Two Bottles-$49.97 a bottle + one bottle is complimentary (includes free shipping)Three Bottles-$39.74 a bottle + receive two complimentary bottles (includes free shipping) Important One Shot Keto Pros and Cons (Benefits): Contributes to the body entering a state of ketosis.It is anti-inflammatory in nature.Ingredient profile that is safe (no harmful One Shot Keto side effects when used as directed.)The directions are simple to follow, and the program is straightforward.It might assist in boosting energy levels.It can assist in boosting the metabolism.It can assist in safely suppressing appetite.May assist in boosting the immune system.Could aid in mental clarity.It could assist in balancing cholesterol levels.It can aid in the rapid loss of body fat.It will assist the body in obtaining proteins, vitamins, and nutrients.It can assist in boosting one's self-esteem.May aid in the fight against oxidative stress.Capsules that are easy to swallow.Simple to follow dosing instructions.May help you feel fuller longer while also decreasing your cravings.The website of the manufacturer is stable.It is a zero-risk investment.Numerous One Shot Keto Reviews on Reddit are favorable. The REAL One Shot Keto Testimonial – “You Will Not Believe What She Said!” (Cons): The Better Business Bureau (BBB) knows very little about the product. This is not always a bad thing. The good news is that there have been no complaints about One Shot Keto as of the time of this article.There are reports that some online retailers are selling counterfeit goods.This item is only available for purchase online. It is often best to make purchases directly from the manufacturer's website.Individual results can vary.The One Shot Keto Shark Tank testimonials are not accurate. It never made an appearance on the program.It can be very costly.There is no next day delivery available.There are no independent testimonials for One Shot Keto available online. On the manufacturer's website, there are positive testimonials.The manufacturer's website contains no scientific references. IMPORTANT: Shocking New One Shot Keto Report - This May Change Your Mind! What Are The Ingredients Used in One Shot Keto? One Shot Keto is comprised of two distinct blends: BHB Ketone and Detox. Both of these blends contain a variety of additional naturally occurring substances. All ingredients are sourced from reputable providers and are checked to ensure you receive the highest-quality product. Additionally, the manufacturers state that they adhere to GMP (Good Manufacturing Practices), the industry's highest standard for testing and manufacturing. The following is a list of the ingredients used to create One Shot Keto. BHB's Exclusive Blend (800mg Per Serving) This patented blend includes a high concentration of nutrients (potassium, calcium, magnesium, and sodium) in addition to a Beta-Hydroxybutyrate (BHB) blend. The nutrients listed above are also known as ketone mineral salts. Apart from assisting the body in entering ketosis, it also benefits the overall wellbeing of the body. Proprietary Detox Blend (300mg Per Serving) The detox proprietary blend is composed of several naturally occurring ingredients; the natural ingredients included in the detox proprietary blend are as follows: Powdered Medium-Chain Triglycerides (MCTs) MCTs (medium-chain triglycerides) are fatty acid chains with a carbon atom count of six to twelve. These MCTs are keto-friendly, which means they'll help you prevent the negative side effects and health complications associated with the keto diet. According to science, MCTs have also been shown to accelerate the process of dietary ketosis. HUGE SAVINGS TODAY: Click Here to Get One Shot Keto at an Exclusive Discounted Price B3 niacin Niacin is a B3 vitamin with a number of health benefits. It has been used to treat a number of conditions, including hyperlipidemia and vitamin B deficiency. Indeed, this vitamin is critical for the body's detoxification process. As the body is detoxified, it is in a better position to cause fat loss. Extract of Green Coffee Beans 2:1 Green coffee bean extract is produced from raw coffee beans and therefore contains a high concentration of antioxidants. Chlorogenic acid, a component of green coffee bean extract, has been shown to promote weight loss, which is extremely beneficial. 4:1 Extract of Green Tea Leaf This ingredient is derived from the Camellia sinensis plant, which is used in the One Shot Keto nutritional supplement. It was discovered for the first time in China. Following that, it spread across the world due to its delectable taste and a plethora of nutritional benefits, the majority of which are a result of the increased levels of potent antioxidants. Green tea contains a high concentration of epigallocatechin, a compound that aids in fat oxidation in the body. Additionally, it can help with hydration, weight loss, and protection against a variety of ailments. Extract of Garcinia Cambogia Garcinia Cambogia is a small fruit with a pumpkin-like appearance. Due to the high concentration of hydroxycitric acid, it has grown in popularity among fitness enthusiasts. This ingredient has been subjected to extensive testing and has been shown to be effective in the treatment of obesity. The garcinia extract in this supplement aids in the removal of visceral fat and total fat content in the body, providing consumers with powerful nutritional benefits while also aiding in weight Extract of Black Pepper Black pepper is a naturally occurring spice that is often used in a variety of keto supplements to aid in digestion and detoxification. This part stimulates sweat and urine production, allowing you to eliminate all unhealthy substances accumulated in your system and detoxify them from the inside out. As a result, digestive processes will be improved, and the body's weight loss capacity will be increased. Also included are: DandelionL-TyrosineRice FlourGelatinSilicon DioxideMagnesium Stearate Our final thoughts. Should you purchase One Shot Keto? One Shot Keto by Limitless is a unique supplement that accelerates the ketosis process in the body. It provides the body with premade ketones, which can result in a fat-burning state and, consequently, weight loss. These pills contain proprietary blends that are 100 percent natural and contain no chemical additives. The price seems to be reasonable, and the money-back guarantee ensures that this is a risk-free investment. Official Website: https://tryoneshot-keto.com Contact Details: OneShot Keto Email: firstname.lastname@example.org Phone: TOLL FREE (844) 423-5386 (KETO) Disclaimer: † Statements in this report have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure or prevent any disease. Individual results may vary. The author is not your doctor or nutritionist and this report is for informational purposes only. Please see your doctor before using any supplement you find here or elsewhere. Any order finalized from this release’s links are subject to the entire terms and conditions of the manufacturer website’s offer. The information in this release report does not take any direct or indirect responsibility for its accuracy. About Researched Reviews: Researched Reviews is a well-respected public source of information and product Review Company situated in the suburbs of Philadelphia, PA, and Southern New Jersey assisting consumers to find important information concerning specified products and services that will then help individuals determine if those specific products and services are in fact a suitable fit for them. Affiliate disclosure: We are never paid to write a review, although, if a visitor makes a purchase from a link on our page, we may receive compensation which helps pay for our ongoing research and reviews. We only give high marks to the best products and services. Researched Reviews reports back on a broad range of both products and services. Researching and reviewing everything from beauty and health benefit care products to services and membership programs that may be popular in the market place at any given time. Researched Reviews remains committed to providing honest and accurate information to consumers at all time. CONTACT: David Kingston Researched Reviews email@example.com
APAC organ care products market is predicted to expand at a CAGR of more than 15.5% till 2027 owing to considerable rise in organ transplantations in emerging countries including China and India.Selbyville, Delaware, April 15, 2021 (GLOBE NEWSWIRE) -- According to latest report “Organ Care Products Market by Organ Type (Kidney, Liver, Heart, Lungs), Product Type (Trolly, Portable), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027”, by Global Market Insights Inc., the market valuation of organ care products will cross $250 million by 2027. Rising demand for efficient organ care products to enhance safety of donor organs during transplantation will foster the market growth. The COVID-19 has impacted various industrial sectors to greater extent with movement restrictions and strict regulations on some healthcare procedures. It has significantly influenced the procedural rate of solid organ transplants in some of majorly affected countries. The pandemic has affected transplant listing and referral processes, thereby leading to decreased transplant procedures. Thus, industry has experienced moderate impact during pandemic, however, with relaxation of restrictions in the latter period of 2020, the companies recovered their revenues considerably. Thus, the industry will continue to grow at substantial pace in foreseeable future with increasing multitude of organ failure due to prevalence of chronic diseases. Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/5026 Technological advancements in organ transplant procedures will boost the adoption of developed organ care systems, thereby offering unprecedented opportunities for the organ care products market expansion during the forecast timeline. The efficiency of advanced system during organ transportation and preservation has fueled the product usage. To augment the product demand and expand customer base, leading the industry players are extensively focusing on expansion of product applications that will further escalate the sales volume. Introduction of fully portable perfusion systems to monitor and maintain organs at metabolically active state will further favor the industrial growth in the coming period. Liver segment in the organ care products market is projected to witness 13.4% growth rate till 2027. As per the data by Global Observatory on Donation and Transplantation, about 34,074 liver transplants were performed in 2018. Additionally, excess consumption of acetaminophen, autoimmune disease, metabolic diseases and toxins contributes in increasing number of liver failures. Miniaturized and portable liver care systems will further impel the product demand in facilities. Thus, increasing product sales with growing demand will positively impact the segment revenue during the forecast timeframe. Trolly segment dominated more than 57% of the organ care products market share in 2020 led by high product cost and its associated benefit of reusability. Trolly based systems are being widely used in organ care centers. Ease and convenience in handling these systems are poised to drive the segment growth in the coming years. Asia Pacific organ care products market is estimated to attain a CAGR of over 15.5% through 2027 on account of considerable increase in organ transplantations in emerging countries including China and India. Large population base suffering from chronic kidney and cardiovascular diseases are at higher risk of organ failure that will offer immense growth opportunities to the market. This will also attract industry leaders with opportunity for the regional expansion. Increasing treatment accessibility and rising acceptance of advanced products in these countries will further foster the industry growth. Moreover, growing medical tourism with lower treatment cost for liver transplants and other surgeries will play a vital role in propelling the growth for APAC region. Request for customization of this research report @ https://www.gminsights.com/roc/5026 Major players operating in the market include TransMedics, XVIVO Perfusion AB, Bridge to Life and Paragonix Technologies, Inc., among others. Companies are implementing various strategies such as product innovations, partnerships and collaborations to gain competitive advantage for the business expansion. Table of Contents (ToC) of the report: Chapter 3 Organ Care Products Market Insights 3.1 Industry segmentation 3.2 Industry landscape, 2016 – 2027 (USD Million) 3.3 Industry impact forces 3.3.1 Growth drivers 3.3.2 Industry pitfalls & challenges 3.4 Growth potential analysis 3.4.1 By organ type 3.4.2 By product type 3.5 COVID-19 impact analysis 3.6 Regulatory landscape 3.7 Porter's analysis 3.8 Competitive landscape, 2020 3.9 PESTEL analysis Browse Complete Table of Contents (ToC) @ https://www.gminsights.com/toc/detail/organ-care-products-market About Global Market Insights Inc. Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology. CONTACT: Contact Us: Arun Hegde Corporate Sales, USA Global Market Insights Inc. Phone: 1-302-846-7766 Toll Free: 1-888-689-0688 Email: firstname.lastname@example.org
Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) ("Columbia Care" or the "Company") announced today the launch of its proprietary solid-fill cannabis powder capsule for medicinal use throughout the United Kingdom. This is the first solid-fill capsule of its kind available in the UK and the first dose-metered medicinal cannabis product to be manufactured in the UK. The capsules are part of Columbia Care’s trademarked Ceed medicinal product range.
Fiverr International Ltd. (NYSE: FVRR), the company that is changing how the world works together, today released its third Small Business Needs Index. The index analyzes data from the millions of searches across the platform. The services small businesses are looking for and search terms they use allow the marketplace to predict what’s important, what’s trending and what’s next for small businesses.
Kempinski Hotels, Europe's oldest luxury hotel group, has partnered with Technogym, the world-leading company in fitness and wellness, to offer its guests an all-round wellness experience that alongside the hotel wellness centre includes innovative in-room training solutions and on-demand fitness services for an exclusive wellness experience.
Faster download speeds and worldwide coverage enhance the AgilePlans Regional offeringMIDDLETOWN, R.I., April 15, 2021 (GLOBE NEWSWIRE) -- KVH Industries, Inc., (Nasdaq: KVHI), announced today that its AgilePlans® Regional solution designed for fishing vessels, workboats, and smaller commercial vessels now features data speeds as fast as 6 Mbps down/2 Mbps up and worldwide coverage providing vessels that typically work in regional waters with greater geographic flexibility. AgilePlans Regional is a Connectivity as a Service (CaaS) subscription-based model that includes a choice of hardware (TracPhone® V30, KVH’s newest and easiest-to-install ultra-compact system or the 37 cm TracPhone V3-HTS antenna with expanded network management), unlimited email and texting, installation in as many as 4,000 ports and locations, cybersecurity protection, KVH OneCare™ maintenance, and no commitment, all for one monthly fee. “The challenges of the pandemic in the past year showed just how important reliable satellite communications are for working vessels and we are committed to ensuring that smaller commercial vessels have access to a solution that meets their needs,” says Mark Woodhead, KVH executive vice president for mobile connectivity. “The no-commitment, all-inclusive AgilePlans model is designed to help fleets upgrade their satcom with no upfront CAPEX costs, which might otherwise be a barrier.”The AgilePlans Regional service complements KVH’s AgilePlans Global service, which is offered with the 60 cm TracPhone V7-HTS (with data speeds as high as 10/3 Mbps down/up) and the 1 meter TracPhone V11-HTS (with data speeds as high as 20/3 Mbps down/up), making AgilePlans available for commercial vessels of all sizes.Throughout the maritime industry, commercial fleets are migrating from legacy L-band systems, where slower data speeds are measured in kilobits per second (Kbps) to VSAT services, such as KVH AgilePlans, where faster data speeds measured in megabits per second (Mbps) enable vessels to improve operational efficiency through digitalization. Vessel operators can use faster connectivity to take advantage of real-time data transfers to improve decision making for fuel optimization, route planning, and safety and to support cloud-based software programs, remote system monitoring, and data analytics. KVH’s TracPhone HTS series antenna systems are designed for KVH’s mini-VSAT BroadbandSM HTS network, which provides global coverage from multi-layered high-throughput satellites (HTS) in the Intelsat FlexMaritime network with additional coverage from SKY Perfect JSAT.KVH is a mobile tech innovator that provides connectivity solutions for commercial maritime, leisure marine, and land mobile applications on vessels and vehicles, including the award-winning TracPhone and TracVision® product lines, the global mini-VSAT Broadband network, and AgilePlans. The company’s KVH Media Group provides news, sports, and entertainment content with such brands as NEWSlink™ and SPORTSlink™. Note to Editors: For more information about AgilePlans, please visit kvh.com/agileplans. High-resolution images of KVH products are available at the KVH Press Room Image Library, kvh.com/Press-Room/Image-Library. About KVH Industries, Inc.KVH Industries, Inc., is a global leader in mobile connectivity and inertial navigation systems, with innovative technology designed to enable a mobile world. A market leader in maritime VSAT, KVH designs, manufactures, and provides connectivity and content services globally. KVH is also a premier manufacturer of high-performance sensors and integrated inertial systems for defense and commercial applications. Founded in 1982, the company is based in Middletown, RI, with research, development, and manufacturing operations in Middletown, RI, and Tinley Park, IL, and more than a dozen offices around the globe. KVH Industries, Inc., has used, registered, or applied to register its trademarks in the U.S.A. and other countries around the world, including but not limited to the following marks: KVH, AgilePlans, TracPhone, KVH OneCare, mini-VSAT Broadband, TracVision, NEWSlink, and SPORTSlink. All other trademarks are the property of their respective companies. For further information, please contact:Jill ConnorsSr. Manager, Media & Industry Analyst RelationsKVH Industries, Inc.Tel: +1 401 851 email@example.com